Skip to content

Fabbro BioPharm Consulting

Active Private limited companyfounded 2019active for 6 yearsDeerlijkstraat 27, 8570 AnzegemKBO/BCE: BE 0739.732.886

Lifetime

5 annual accounts with figures on one time axis
peak of €571,709 in 2021
€158,737▼ 43.9%
peak of €373,071 in 2021
€113,359▼ 41.5%
peak of €732,063 in 2025
€732,063▲ 18.3%
€25,835▼ 59.9%
Board1 name since 2019
1 director
Documentsfilings and deeds
28-04-20262 days before the deadline
2025micro format
Gross margin from €282,846 to €158,737Result from €193,654 to €113,359Equity from €618,704 to €732,063Debts from €64,358 to €25,835Cash from €428,286 to €713,856

Key points

from the 2025 annual accounts

Equity

€732,063 ▲ 18.3%

Fabbro BioPharm Consulting has made a profit in every financial year since 2021.

Result

€113,359 ▼ 41.5%
€194,0002024€113,0002025

The result fell in 2025 from €193,654 to €113,359.

Turnover

≈ €290,000 estimated

The micro format states no turnover.

Liquidity

52.44 was 12.50 in 2024

Short-term debts fell from €54,388 to €14,435.

Filings

5 annual accounts since 2021
deadline20222024

The last five annual accounts were filed 0 to 57 days before the end of the period.

Position in the sector

96.6%

Higher solvency than 95% of companies in advertising and market research. The sector median is 53.2%, over 9,136 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 6,785 companies had the same profile as Fabbro BioPharm Consulting has now. Each dot stands for 17 companies, two years later.

96.7%
were still trading
2.7%
stopped another way
0.6%
went bankrupt
  • Small
  • 5 to 10 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 6,785 companies, not a prediction for Fabbro BioPharm Consulting. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, since 12-12-2019
  • founderdeed of 20-12-2019
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0739732886
Incorporation Founding capital of €5,000, 100 shares · Founded by · appointed as director · published on 20-12-2019 · Gazette deed
First establishment Deerlijkstraat 27, Anzegem
All 12 events

Comparable companies

same main activity, similar in size and age
Company
Fabbro BioPharm Consulting Anzegem €757,898 €158,737 96.6% -
CVS Consulting Schilde €823,892 €152,691 95.3% -
Wambach Ghent €764,028 €126,921 16.6% -
VS CONSULTING Soignies €712,902 €137,606 27.3% -
DV Consult Pecq €624,779 €180,369 90.7% -
GREENOVE HOLDING Incourt €747,491 €160,253 59.3% -
Leave it to me communication and project management Koksijde €703,189 €139,854 46.0% -

These companies have the same main activity as Fabbro BioPharm Consulting: public relations and communication consultancy (NACE 73300). They are comparable in size and age: total assets between €625,000 and €824,000, founded between 2018 and 2021.

Official details

Source: KBO
Status
Active since 18-12-2019Normal situation
Activity
Public relations and communication consultancyNACE 73300
Establishment unit
2.297.214.2778570 Anzegem, since 18-12-2019
Financial year end
30 September
Peppol
Reachable since 21-12-2025
Company details

Annual accounts to 30-09-2025

€757,898▲ 11.0%
Filing
Filed on 28-04-2026, 2 days before the end of the filing period
Financials

Insights on Fabbro BioPharm Consulting

Fabbro BioPharm Consulting files the micro format. That format states no turnover. The gross margin fell from €571,709 in 2021 to €158,737 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Fabbro BioPharm Consulting

What is the company number of Fabbro BioPharm Consulting?
The company number of Fabbro BioPharm Consulting is 0739.732.886. The VAT number is the same number with BE in front: BE 0739.732.886.
Where is Fabbro BioPharm Consulting based?
The registered office is at Deerlijkstraat 27, 8570 Anzegem.Company details
What does Fabbro BioPharm Consulting do?
According to the KBO register, the main activity is public relations and communication consultancy (NACE 73300).
What is the legal form of Fabbro BioPharm Consulting?
Fabbro BioPharm Consulting is a private limited company (BV).
When was Fabbro BioPharm Consulting founded?
Fabbro BioPharm Consulting was founded on 18-12-2019.
Is Fabbro BioPharm Consulting still active?
Yes, Fabbro BioPharm Consulting is an active enterprise in the KBO register.
What is the turnover of Fabbro BioPharm Consulting?
The turnover in financial year 2025 is about €290,000. This figure is estimated from the gross margin of €158,737 and 38 comparable companies (NACE 73). It probably lies between €220,000 and €580,000.Financials
Is Fabbro BioPharm Consulting profitable?
In financial year 2025, Fabbro BioPharm Consulting made a profit of €113,359.
Where can I find the annual accounts of Fabbro BioPharm Consulting?
Fabbro BioPharm Consulting filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Fabbro BioPharm Consulting due?
Fabbro BioPharm Consulting must file the annual accounts for financial year 2026 by 30-04-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.